• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

chronic lymphocytic leukaemia (CLL) - Articles and news items

First biosimilar mAb in oncology granted EU approval

Industry news / 23 February 2017 / Niamh Marriott, Digital Editor

The European Commission has approved Truxima (biosimilar rituximab) for all indications of reference rituximab in the European Union (EU)…

NICE does not recommend AbbVie’s leukaemia drug

Industry news / 16 February 2017 / Niamh Marriott, Digital Editor

The incremental cost-effectiveness ratios (ICERs) for venetoclax compared with best supportive care were higher than the normally range…

Verastem licenses Duvelisib from Infinity Pharmaceuticals for $28 million

Industry news / 3 November 2016 / Niamh Louise Marriott, Digital Content Producer

Verastem licensed exclusive worldwide rights to develop and commercialise Infinity’s oncology product candidate duvelisib…

AbbVie receives CHMP positive opinion for Venclyxto (venetoclax) to treat chronic lymphocytic leukaemia

Industry news / 18 October 2016 / Niamh Louise Marriott, Digital Content Producer

The CHMP recommends approval of venetoclax monotherapy in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have…

FDA approves Genmab’s ofatumumab for relapsed CLL

Industry news / 31 August 2016 / Niamh Louise Marriott, Digital Content Producer

Approval is supported by the Phase III complement study that evaluated ofatumumab in combination with FC versus FC alone in patients with relapsed CLL…

 

Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringWATCH NOW
+ +